Talis Biomedical (NASDAQ:TLIS) Stock Price Down 1.7% – What’s Next?

Talis Biomedical Co. (NASDAQ:TLIS)’s share price dropped 1.7% during trading on Tuesday . The company traded as low as $1.77 and last traded at $1.77. Approximately 139 shares changed hands during trading, a decline of 99% from the average daily volume of 13,211 shares. The stock had previously closed at $1.80.

Talis Biomedical Stock Up 2.2 %

The firm has a market capitalization of $3.31 million, a price-to-earnings ratio of -0.06 and a beta of 1.58. The stock has a 50-day moving average price of $1.76 and a 200 day moving average price of $4.89.

Hedge Funds Weigh In On Talis Biomedical

A hedge fund recently raised its stake in Talis Biomedical stock. BML Capital Management LLC grew its position in Talis Biomedical Co. (NASDAQ:TLIS) by 481.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 248,702 shares of the company’s stock after acquiring an additional 205,959 shares during the quarter. Talis Biomedical comprises approximately 0.3% of BML Capital Management LLC’s portfolio, making the stock its 24th biggest position. BML Capital Management LLC owned approximately 13.66% of Talis Biomedical worth $460,000 at the end of the most recent quarter. Institutional investors own 43.77% of the company’s stock.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.